Document is current

Article History

Received: 12 November 2024

Accepted: 27 July 2025

First Online: 13 August 2025

Change Date: 1 September 2025

Change Type: Update

Change Details: The original publication was modified to update affiliation 1.

Declarations

:

: The survey was registered and approved by the data responsible institute (Capital Region of Denmark, P-2021-684in accordance with the Danish Data Protection Agency’s regulations. Under Danish law, this type of study does not require further formal ethical approval. All participants were informed about the study’s purpose, assured that their participation was voluntary, and guaranteed that results would be anonymized. Verbal and written consent was obtained from interview participants, while survey participants consented to participate by initiating the electronic questionnaire.

: Not applicable.

: Caroline Sindet-Pedersen, Nina Føns, Simone Mørck, Gunnar Gislason, Morten Schou, Mohamad El-Chouli, Mikkel Porsborg Andersen, Jenny Bjerre, report no competing interests, Nina Nouhravesh: Speaker fees from Astra Zeneca and Bayer, Anette arnbjerg Højen: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, MSD, Pfizer, Leo Pharma and BMS, Morten Lamberts: payment for honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Pfizer, Bayer, Astra Zeneca, advisory board, Pfizer and Astra Zeneca. Erik Lerkevang Grove: has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Novo Nordisk, Lundbeck Pharma and Organon. He is an investigator in clinical studies sponsored by AstraZeneca, Idorsia or Bayer and has received unrestricted research grants from Boehringer Ingelheim.